Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 2016

View Archived Issues

miRagen Therapeutics and the ALS Association receive grant to develop ALS therapy

High endostatin levels may provide protective effect against cardiovascular events

Phase I study determines regimen for palbociclib with 5-fluorouracil in advanced solid tumors

Terumo launches HeartSheet in Japan

EpimAb Biotherapeutics announces agreement with Innovent Biologics

Protalix BioTherapeutics initiates global phase III study of PRX-102 in Fabry disease

GlaxoSmithKline discloses NAD-dependent SIRT1 activators

Medgenics collaborates with Kyowa Hakko Kirin on anti-LIGHT monoclonal antibody for pediatric IBD

Takeda Pharmaceutical and Roivant Sciences form Myovant Sciences

GeoVax begins HBV vaccine development program

Seres Therapeutics signs agreement with the Mayo Clinic

RealStar Zika virus test available in U.S.

Ocular Therapeutix's phase III trial of Dextenza does not meet primary endpoint

Adamis Pharmaceuticals receives FDA response on Epinephrine Injection

FDA approves Allergan's FDC Byvalson for hypertension

FDA requests further data to enable review of eteplirsen NDA

Scientists identify two novel mutations causing type I hyperlipoproteinemia

Vonosap and Vonopion packs launched in Japan for H. pylori eradication

TRX-518 is safe in patients with advanced solid tumors

Fusion peptide of HIV-1 as target for vaccine design

Targeting kynurenine pathway as promising therapeutic strategy for neurodegenerative disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...